Saxagliptin/metformin extended-release (xr) for the type 2 diabetes (T2DM) treatment in Venezuela: a budget impact analysis.

ELGART JORGE; GONZALEZ LORENA; PEREZ MONTEVERDE; GARRIDO LECCA S; AIELLO ELEONORA; GAGLIARDINO JJ

Congreso; ISPOR 19th International Meeting, Montreal, Canadá.; 2014

OBJECTIVES: To estimate the budget impact of the use of saxagliptin/metformin XR fixed-dose combination compared to the current treatment of people with T2DM, in Venezuela. METHODS: We used an MS Excel-based budget impact model assuming coverage of one million people in the health care system of Venezuela, with a 3-year time horizon. DM prevalence was obtained from published literature. Pharmaceutical expenses of oral antidiabetic agents (OADs) were analyzed excluding other medical costs. The cost of OADs was based upon list prices, expressed in Venezuelan Bolivars (VEF$) 2013 (exchange rate: 1 US-dollar = 6.30 VEF$). The market share of the different drugs was based upon QUALIDIAB Database, market studies and data provided by Bristol-Myers Squibb. A progressive increase of market share was assumed for saxagliptin/metformin XR among all the OADs; 1.14%, 2.65% and 3.0% for the 1st, 2nd and 3rd year, respectively. The budget impact is reported in terms of annual budget impact, per member per-month (PMPM) and per patient per month (PPPM). A Monte Carlo simulation (10,000 iterations) was done as part of the sensitivity analysis. RESULTS: the net budget impact estimated for the introduction of saxagliptin/metformin XR combined was VEF$503,807 for the first year, VEF$1,183,333 for the second year and VEF$1,353,554 for the third year; the cumulative net budget impact was VEF$3,040,703. PMPM was VEF$0.04, VEF$0.10 and VEF$0.11 for the first, second and third year respectively. PPPM was VEF$1.67, VEF$4.0 and VEF$4.65 each year, respectively. The cumulative impact in the total annual budget for oral antidiabetic agents represented an increase of 2.36%. Monte Carlo simulation showed that cumulative budget impact varied from 1.32 to 8.74%. CONCLUSIONS: incorporation of saxagliptin/metformin XR combination into the health care system of Venezuela, as a treatment option for people with T2DM, would have a minimal budgetary impact.